Loading...
•
Mar 31, 2020
Denali Therapeutics Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020 and provided an update on the Company's response to COVID-19.
Key Takeaways
Denali Therapeutics reported a net loss of $56.8 million for the first quarter of 2020, compared to a net loss of $39.0 million for the same period in 2019. Collaboration revenue decreased slightly, while research and development expenses increased due to the progression of Denali's portfolio.
Net loss was $56.8 million, compared to $39.0 million for the three months ended March 31, 2019.
Collaboration revenue was $3.6 million, compared to $4.2 million for the three months ended March 31, 2019.
Research and development expenses were $51.0 million, compared to $37.4 million for the three months ended March 31, 2019.
Cash, cash equivalents, and marketable securities were $596.9 million as of March 31, 2020.
Forward Guidance
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's response to COVID-19, including status of clinical trials as well as efforts to mitigate any negative impact on the Company’s research, clinical trials and other business operations; status of pipeline, including the clinical trial for DNL310 in Hunter syndrome patients; and statements made by Denali’s Chief Executive Officer.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...